ReP USP - Resultado da busca

Artigo de periodico
Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial (2020)
Nicolau, José Carlos ; Bhatt, Deepak L; Hohnloser, Stefan H; Kimura, Takeshi; Lip, Gregory Y. H; Miede, Corinna; Nordaby, Matias; Oldgren, Jonas; Steg, Philippe Gabriel; Berg, Jurrien M. ten
Source: Drugs. Unidade: FM
Subjects: ANTICOAGULANTES, ESTUDOS PROSPECTIVOS, FIBRILAÇÃO ATRIAL, QUIMIOTERAPIA COMBINADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, José Carlos et al. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, v. 80, n. 10, p. 995-1005, 2020Tradução . . Disponível em: https://doi.org/10.1007/s40265-020-01323-x. Acesso em: 17 nov. 2024.
APA
Nicolau, J. C., Bhatt, D. L., Hohnloser, S. H., Kimura, T., Lip, G. Y. H., Miede, C., et al. (2020). Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial. Drugs, 80( 10), 995-1005. doi:10.1007/s40265-020-01323-x
NLM
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Vancouver
Nicolau JC, Bhatt DL, Hohnloser SH, Kimura T, Lip GYH, Miede C, Nordaby M, Oldgren J, Steg PG, Berg JM ten. Dabigatran dual therapy vs warfarin triple therapy post-percutaneous coronary intervention in patients with atrial fibrillation with/without a proton pump inhibitor: a pre-specified analysis of the RE-DUAL PCI trial [Internet]. Drugs. 2020 ; 80( 10): 995-1005.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1007/s40265-020-01323-x
Artigo de periodico
Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial (2019)
Steg, Philippe Gabriel; Szarek, Michael; Bhatt, Deepak L; Bittner, Vera A; Bregeault, Marie-France; Dalby, Anthony J; Diaz, Rafael; Edelberg, Jay M; Goodman, Shaun G; Nicolau, José Carlos
Source: Circulation. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, DOENÇAS CARDIOVASCULARES, ANTICORPOS MONOCLONAIS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, v. 140, n. 2, p. 103-112, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.118.038840. Acesso em: 17 nov. 2024.
APA
Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Bregeault, M. -F., Dalby, A. J., et al. (2019). Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial. Circulation, 140( 2), 103-112. doi:10.1161/CIRCULATIONAHA.118.038840
NLM
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Vancouver
Steg PG, Szarek M, Bhatt DL, Bittner VA, Bregeault M-F, Dalby AJ, Diaz R, Edelberg JM, Goodman SG, Nicolau JC. Effect of alirocumab on mortality after acute coronary syndromes an analysis of the ODYSSEY OUTCOMES randomized clinical trial [Internet]. Circulation. 2019 ; 140( 2): 103-112.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.118.038840
Artigo de periodico
Physical Activity and Mortality in Patients With Stable Coronary Heart Disease (2017)
Stewart, Ralph A. H.; Hadziosmanovic, Nermin; Armstrong, Paul W.; Cannon, Christopher P.; Granger, Christopher B.; Hagström, Emi; Hochman, Judith S.; Koenig, Wolfgang; Lonn, Eva; Nicolau, José C.; Steg, Philippe Gabriel; Vedin, Ola; Wallentin, Lars; White, Harvey D.
Source: Journal of the American College of Cardiology. Unidade: FM
Subjects: DOENÇAS CARDIOVASCULARES, MORTALIDADE, ATIVIDADE FÍSICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEWART, Ralph A. H. et al. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, v. 70, n. 11, p. 1689-1700, 2017Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2017.08.017. Acesso em: 17 nov. 2024.
APA
Stewart, R. A. H., Hadziosmanovic, N., Armstrong, P. W., Cannon, C. P., Granger, C. B., Hagström, E., et al. (2017). Physical Activity and Mortality in Patients With Stable Coronary Heart Disease. Journal of the American College of Cardiology, 70( 11), 1689-1700. doi:10.1016/j.jacc.2017.08.017
NLM
Stewart RAH, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease [Internet]. Journal of the American College of Cardiology. 2017 ; 70( 11): 1689-1700.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jacc.2017.08.017
Vancouver
Stewart RAH, Hadziosmanovic N, Armstrong PW, Cannon CP, Granger CB, Hagström E, Hochman JS, Koenig W, Lonn E, Nicolau JC, Steg PG, Vedin O, Wallentin L, White HD. Physical Activity and Mortality in Patients With Stable Coronary Heart Disease [Internet]. Journal of the American College of Cardiology. 2017 ; 70( 11): 1689-1700.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1016/j.jacc.2017.08.017
Artigo de periodico
Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial (2013)
Steg, Philippe Gabriel; Mehta, Shamir R.; Pollack Jr, Charles V.; Bode, Christoph; Cohen, Marc; French, William J.; Hoekstra, James; Rao, Sunil V.; Ruzyllo, Witold; Ruiz-Nodar, Juan M.; Sabaté, Manel; Widimsky, Petr; Kiss, Robert Gabor; Estrada, Jose Luis Navarro; Hod, Hanoch; Kerkar, Prafulla; Guneri, Sema; Sezer, Murat; Ruda, Mikhail; Nicolau, José Carlos; Cavallini, Claudio; Ebrahim, Iftikhar; Petrov, Ivo; Kim, Jae-Hyung; Jeong, Myung-Ho; Lopez, Gabriel Arturo Ramos; Laanmets, Peep; Kovar, Frantisek; Gaudin, Christophe; Fanouillere, Karen C.; Minini, Pascal; Hoffman, Elaine B.; Moryusef, Angele; Wiviott, Stephen D.; Sabatine, Marc S.
Source: JAMA: Journal of the American Medical Association. Unidade: FM
Subjects: ANTICOAGULANTES, ISQUEMIA, DOENÇA AGUDA, CORONARIOPATIA (TERAPIA)
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, Philippe Gabriel et al. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial. JAMA: Journal of the American Medical Association, v. 310, n. 11, p. 1145-1155, 2013Tradução . . Disponível em: https://doi.org/10.1001/jama.2013.277165. Acesso em: 17 nov. 2024.
APA
Steg, P. G., Mehta, S. R., Pollack Jr, C. V., Bode, C., Cohen, M., French, W. J., et al. (2013). Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial. JAMA: Journal of the American Medical Association, 310( 11), 1145-1155. doi:10.1001/jama.2013.277165
NLM
Steg PG, Mehta SR, Pollack Jr CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Estrada JLN, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim J-H, Jeong M-H, Lopez GAR, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial [Internet]. JAMA: Journal of the American Medical Association. 2013 ; 310( 11): 1145-1155.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1001/jama.2013.277165
Vancouver
Steg PG, Mehta SR, Pollack Jr CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Estrada JLN, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim J-H, Jeong M-H, Lopez GAR, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS. Anticoagulation With Otamixaban and Ischemic Events in Non–ST-Segment Elevation Acute Coronary Syndromes: The TAO Randomized Clinical Trial [Internet]. JAMA: Journal of the American Medical Association. 2013 ; 310( 11): 1145-1155.[citado 2024 nov. 17 ] Available from: https://doi.org/10.1001/jama.2013.277165

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em